Skip to content

Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete

A Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Dietary Supplement BioAmicus Complete (Oral Drops; a Mixture of 10 Strains of Lacto- and Bifidobacteria) in Managing Functional Gastrointestinal Disorders and Cutaneous Symptoms of Food Allergy in Infants During the First Months of Life

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07444008
Enrollment
140
Registered
2026-03-02
Start date
2026-03-16
Completion date
2026-07-30
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Constipation, Infantile Colics, Infantile Diarrhea

Brief summary

This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional gastrointestinal disorders and cutaneous symptoms of food allergy in infants during the first months of life. The aim of the study is to assess clinical effects of BioAmicus Complete drops on the symptoms of infantile colic, constipation, diarrhea, gastroesophageal reflux, atopic dermatitis/eczema in full-term newborns during the first months of life. A prospective study comparing two treatment groups: Group 1 (treatment group) - 70 infants. Group 2 (control group) - 70 infants, placebo. The study drug will be taken in 1 time per day within 25 days. Allowed symptomatic therapy includes defoamers (simethicone-based preparations), carminative preparations (dill water (fenhel)), etc.

Interventions

DIETARY_SUPPLEMENTBioAmicus Complete

BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria)

DIETARY_SUPPLEMENTPlacebo

Sunflower oil

Sponsors

NovoNatum Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
1 Months to 5 Months
Healthy volunteers
No

Inclusion criteria

* The child's parents/guardians speak Russian, have been informed about the study's purpose, understand its essence, are aware of their rights, and have signed the informed consent form. * Diarrhea or constipation accompanied by colic and/or regurgitation (gastroesophageal reflux, GER). * Cutaneous manifestations of food allergy. * The child was born at term or preterm, but not before the 7th month of gestation. * Age at the time of parental informed consent: from 1 month to 4 months and 28 days. * The child is on breastfeeding, formula feeding, or mixed feeding. * The child has no other health conditions that would require a specialized diet. * The parents/guardians are able and willing to regularly complete the proposed observation diary form.

Exclusion criteria

* The child has a congenital pathology or any other conditions/diseases/clinical manifestations that may interfere with participation in the study. * Use of lactase supplements. * Use of other probiotic products, antibiotics, enteral antiseptics, antifungal, or antiprotozoal medications. * The child was born preterm (before the 7th month of gestation).

Design outcomes

Primary

MeasureTime frameDescription
Constipation or diarrhea28 daysassessed by changes in stool frequency \[number of bowel movements\] and perceived ease of defecation. Episodes per day.
Frequency and duration of colic28 daysassessed by changes in the number of colic episodes, number of crying episodes, and average duration of crying. Episodes per day and duration in minutes.
Gastroesophageal reflux28 daysGER, assessed by changes in the number of GER episodes per day

Secondary

MeasureTime frameDescription
Cutaneous manifestations of food allergy.28 daysNumber of patientswithhe presence or absence of clinical manifestations of skin symptoms of food allergy (atopic dermatitis/eczema)
Weight increase28 daysChange in body weight relative to the baseline

Countries

Russia

Contacts

CONTACTOleg Tyrsin
vb@novonatum.com+7 985 784 3151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 12, 2026